To view this email as a web page,
click here | It's safe to say this year's ASCO will be one of a kind, and today's round of news proves it. Rather than wait until its virtual conference later this month, the organization lifted the veil today on almost all the new studies set for presentation. Here are our two top picks. For the skinny on 16 more, visit FiercePharma and FierceBiotech. | | | Wednesday, May 13, 2020 The more checkpoint inhibitors the merrier—at least that’s what Genentech is hoping to prove. Its PD-L1 blocker Tecentriq combined with its experimental anti-TIGIT antibody shrank tumors in 31% of patients with metastatic lung cancer—twice as many patients as Tecentriq alone. The findings could pave the way for an approach that makes checkpoint inhibitors work for more people. |
|
|---|
|
| | | Wednesday, May 13, 2020 When Bristol-Myers said its combination of Opdivo, Yervoy and chemo had topped solo chemo at lengthening lung cancer patients’ lives, analysts and investors wondered if the three-drug regimen had spurred a survival benefit on par with Merck’s market-leading Keytruda-chemo combo. Spoiler alert: It didn't, strictly comparing the numbers between trials. But the way Bristol sees it, there are plenty of other factors at play. |
|
|---|
|
|
|
